Switch theme
Sign up to access all valuation multiples
Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.
2023
143
Last FY Revenue $37.0M
Last FY EBITDA $16.2M
$102M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Baird Medical Investment achieved revenue of $37.0M and an EBITDA of $16.2M.
Baird Medical Investment expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Baird Medical Investment valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $37.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $32.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 88% | XXX | XXX | XXX |
| EBITDA | XXX | $16.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 44% | XXX | XXX | XXX |
| EBIT | XXX | $15.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 41% | XXX | XXX | XXX |
| Net Profit | XXX | $12.5M | XXX | XXX | XXX |
| Net Margin | XXX | 34% | XXX | XXX | XXX |
| Net Debt | XXX | $17.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Baird Medical Investment's stock price is $2.
Baird Medical Investment has current market cap of $84.4M, and EV of $102M.
See Baird Medical Investment trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $84.4M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Baird Medical Investment has market cap of $84.4M and EV of $102M.
Baird Medical Investment's trades at 2.8x EV/Revenue multiple, and 6.3x EV/EBITDA.
Equity research analysts estimate Baird Medical Investment's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Baird Medical Investment's P/E ratio is not available.
See valuation multiples for Baird Medical Investment and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $84.4M | XXX | $84.4M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 6.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 6.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -11.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBaird Medical Investment's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Baird Medical Investment's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Baird Medical Investment's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Baird Medical Investment and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 44% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Baird Medical Investment acquired XXX companies to date.
Last acquisition by Baird Medical Investment was XXXXXXXX, XXXXX XXXXX XXXXXX . Baird Medical Investment acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Baird Medical Investment founded? | Baird Medical Investment was founded in 2023. |
| Where is Baird Medical Investment headquartered? | Baird Medical Investment is headquartered in United States of America. |
| How many employees does Baird Medical Investment have? | As of today, Baird Medical Investment has 143 employees. |
| Who is the CEO of Baird Medical Investment? | Baird Medical Investment's CEO is Ms. Haimei Wu. |
| Is Baird Medical Investment publicy listed? | Yes, Baird Medical Investment is a public company listed on NAS. |
| What is the stock symbol of Baird Medical Investment? | Baird Medical Investment trades under BDMD ticker. |
| When did Baird Medical Investment go public? | Baird Medical Investment went public in 2024. |
| Who are competitors of Baird Medical Investment? | Similar companies to Baird Medical Investment include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Baird Medical Investment? | Baird Medical Investment's current market cap is $84.4M |
| Is Baird Medical Investment profitable? | Yes, Baird Medical Investment is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
